Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

Sunday, July 5, 2020

Primary & Secondary Secondary TMAU, updates on treatment & research 2020

Click on icon
for full paper

"Treatments of trimethylaminuria: where we are and where we might be heading", Aaron C. Schmidt and Jean-Christophe Leroux, of the Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Zurich, Switzerland,

  • Presents a good description of Primary and Secondary TMAU,
  • Discussion on the pros and cons of TMAU treatment options and ongoing research directly or indirectly related to TMAU,
  • Discussion on ongoing research directly and indirectly related to TMAU.

Definition of Secondary TMAU:

Secondary TMAU
Often referred to as acquired or sometimes transient TMAU, people becoming afflicted with secondary TMAU might show prolonged symptoms. This form of the disorder can occur in a variety of different scenarios. Treatment with choline in Huntington’s and Alzheimer’s diseases has been associated with the development of a strong fishy body odor [26,27], and is a classic example of precursor overload where the enzyme is unable to completely oxidize the TMA burden. Liver failure and portosystemic shunting of the blood can also result in increased TMA levels, owing to interference with first-pass metabolism [28,29]. Other factors that have been reported to cause or exacerbate the condition (including primary TMAU) encompass menstruation [30,31], asymptomatic viral hepatitis [32] and testosterone treatment [33], and have been reviewed elsewhere [4].
Treatments of trimethylaminuria: where we are and where we might be heading

Treatment options discussed:

  1. Limiting precursor intake
  2. Protonation of TMA
  3. Targeting gut metabolism
  4. Antibiotics
  5. Probiotics, including Methanogenic archaebiotics, Fecal microbial Transplantation (FMT).

Some ongoing research studies:

Fecal Microbial Transplantation

In the Fecal microbial transplantation (FMT) discussion, the authors present findings reported by Dr. Stanley Hazen, MD, et al. while studying FMT in the context of CVD [105]. Since Dr. Hazen's focus is on on the results of TMAO levels in the blood, as opposed to TMA levels, even though TMAO levels in serum leveled out after 16-20 weeks of FMT, it does not necessarily translate into reduction in TMA. Therefore, further research with TMA being the focus, as opposed to TMAO, is needed.
Gregory, J.C. et al. (2015) Transmission of atherosclerosis susceptibility with gut microbial transplantation. J. Biol. Chem. 20, 5647-5660

 DMB and Aspirin

Dr. Hazen's research on DMB and aspirin (2012, 2013, 2015):

In 2012, Hazen et al. patented the small molecule 3,3-dimethyl-1-butanol (DMB) and similar compounds for their ability to lower intestinal TMA in the treatment of CVD [108]. After observing decreased TMA production from choline in mouse cecum in vitro, DMB was administered to C57BL/6J mice in drinking water, resulting in a reduction of urinary and plasma TMA levels. The proposed mechanism of action was the inhibition of several TMA lyases, including choline TMA lyase, as determined in vitro [109]. The patent was further extended to acetylsalicylic acid (ASA) and its derivatives, because ASA showed inhibition of TMA lyase activity of Proteus mirabilis – a microbe with abundant TMA lyase activity in an in vitro setup [110].

[108] Hazen, S.L. et al. (2013) Treatment and prevention of cardiovascular disease and thrombosis. US9168233B2.
Google Scholar

[109] Z. Wang, et al.
Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis
Cell, 163 (2015), pp. 1585-1595
Download PDF

[110] Hazen, S.L. (2015) Treating and preventing disease with tma and tmao lowering agents US20160089386A1.
Google Scholar



María de la Torre
Founder and Executive Director

A Public Charity
MEBO's Blog (English)
El Blog de MEBO (español)

Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.

get New Posts by EMAIL : Enter your email address :

A EURORDIS and NORD Member Organization


Anonymous said...

Would combining resveratrol and aspirin have a similar effect? I'm going to try it right away!

Jul 7, 2020, 2:41:00 AM
Post a Comment